Review
Clinical Neurology
Todd E. Golde
Summary: Scientific advances have brought optimism to the field of Alzheimer's disease, but the disease is still largely untreatable. The article reviews the major therapeutic approaches and open questions, and discusses the need to adjust our approach to ensure future success.
Article
Multidisciplinary Sciences
Soo Hyun Cho, Sookyoung Woo, Changsoo Kim, Hee Jin Kim, Hyemin Jang, Byeong C. Kim, Si Eun Kim, Seung Joo Kim, Jun Pyo Kim, Young Hee Jung, Samuel Lockhart, Rik Ossenkoppele, Susan Landau, Duk L. Na, Michael Weiner, Seonwoo Kim, Sang Won Seo
Summary: This study aimed to construct a disease course model from preclinical AD to AD dementia, finding that ADAS-cog 13 scores decreased most rapidly in women APOE epsilon 4 carriers and most slowly in men APOE epsilon 4 non-carriers. The results suggest that both sex and APOE epsilon 4 status have an impact on the progression of AD.
SCIENTIFIC REPORTS
(2021)
Review
Chemistry, Multidisciplinary
Yilong Xi, Yun Chen, Yi Jin, Guochen Han, Mingjie Song, Tingting Song, Yang Shi, Ling Tao, Zewei Huang, Jianping Zhou, Yang Ding, Huaqing Zhang
Summary: This article summarizes the complex pathogenesis of Alzheimer's disease (AD) and the interaction between different therapeutic targets. It discusses the key challenges in translating anti-AD nanomedicine from benchtop to bedside and highlights the recent advances in exploring pathogenesis-inspired nanomaterials in AD treatment.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Clinical Neurology
Johanna Thunell, Yi Chen, Geoffrey Joyce, Douglas Barthold, Paul G. Shekelle, Roberta Diaz Brinton, Julie Zissimopoulos
Summary: The study identified 29 drug classes associated with increasing or decreasing ADRD risk, with a need for further research in certain areas. Some areas of study still have limited evidence and require more data to support conclusions.
ALZHEIMERS & DEMENTIA
(2021)
Article
Psychology, Clinical
Leah M. Cohen, Eleanor Ash, John D. Outen, Ryan Vandrey, Halima Amjad, Marc Agronin, M. Haroon Burhanullah, Patricia Walsh, James M. Wilkins, Jeannie-Marie Leoutsakos, Milap A. Nowrangi, David Harper, Paul B. Rosenberg, Brent P. Forester
Summary: Agitation is a common complication of Alzheimer's dementia associated with negative impacts on patients and care partners, and there are currently no FDA-approved pharmacological treatments. An ongoing study is investigating the safety and efficacy of dronabinol in treating Agit-AD, with preliminary results showing a predominantly female, white sample with advanced cognitive impairment.
INTERNATIONAL PSYCHOGERIATRICS
(2021)
Article
Clinical Neurology
Aliza P. Wingo, Selina M. Vattathil, Jiaqi Liu, Wen Fan, David J. Cutler, Allan Levey, Julie A. Schneider, David A. Bennett, Thomas S. Wingo
Summary: This study found that LDL-C is associated with various neuropathological manifestations of AD independent of APOE, suggesting that LDL-C may be a modifiable risk factor for AD.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Review
Clinical Neurology
Thomas Doherty, Zhi Yao, Ahmad A. l. Khleifat, Hanz Tantiangco, Stefano Tamburin, Chris Albertyn, Lokendra Thakur, David J. Llewellyn, Neil P. Oxtoby, Ilianna Lourida, Janice M. Ranson, James Duce
Summary: Drug discovery and clinical trial design for dementia have always been challenging due to patient heterogeneity, disease course length, and the tractability of brain targets. Big data analytics and machine learning tools show potential in accelerating progress by informing clinical trial design and drug discovery. However, several challenges need to be overcome and a multi-disciplinary approach is required for data-driven decision-making to reach its full potential. This review discusses the current state of machine learning applications in clinical trial design and drug discovery, while providing opportunities and recommendations to overcome implementation barriers.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Sara K. Quinney, Kandasamy Murugesh, Adrian Oblak, Kristen D. Onos, Mike Sasner, Anna K. Greenwood, Kara H. Woo, Stacey J. Sukoff Rizzo, Paul R. Territo
Summary: We propose an unbiased methodology for ranking compounds for preclinical testing in Alzheimer's disease (AD) in order to enhance successful translation to the clinic. Previously compound selection was based solely on physiochemical properties, making ranking challenging. The STOP-AD framework overcomes this limitation by evaluating drug-like properties and performing Monte-Carlo simulations. Highlights: Promising preclinical studies for AD drugs have not translated to clinical success. Systematic assessment of AD drug candidates may increase clinical translatability. We describe a well-defined compound selection framework with clear selection metrics.
ALZHEIMERS & DEMENTIA
(2023)
Review
Pharmacology & Pharmacy
Micaela Riscado, Bruno Baptista, Fani Sousa
Summary: Dementia is the fifth leading cause of death worldwide, with Alzheimer's disease being the most common and having a significant impact on patients' health and quality of life. The pathologic process is characterized by amyloid deposition, Tau phosphorylation, and neurodegeneration, but it is still unclear how these events are connected to disease progression.
Review
Clinical Neurology
Claire Sexton, Michele Solis, Judith Aharon-Peretz, Panagiotis Alexopoulos, Liana G. Apostolova, Eleonore Bayen, Betty Birkenhager, Stefano Cappa, Fofi Constantinidou, Juan Fortea, Debby L. Gerritsen, Hany Hassanin, Agustin Ibanez, Panagiotis Ioannidis, Elissaios Karageorgiou, Amos Korczyn, Iracema Leroi, Bjorn Lichtwarck, Giancarlo Logroscino, Chris Lynch, Patrizia Mecocci, Jose Luis Molinuevo, John Papatriantafyllou, Sokratis Papegeorgiou, Antonis Politis, Rema Raman, Karen Ritchie, Pascual Sanchez-Juan, Mary Sano, Nikolas Scarmeas, Luiza Spiru, Afroditi Stathi, Magda Tsolaki, Gorsev Yener, Ioannis Zaganas, Stelios Zygouris, Maria Carrillo
Summary: With the increasing research and services in the Mediterranean region, there are growing opportunities for global collaboration. The virtual Alzheimer's Association International Conference provided a platform for researchers to share updates on the understanding, treatment, and care of Alzheimer's disease and other dementias in the Mediterranean region. The conference highlighted the local epidemiology of AD and dementia, identified populations for genetic studies, emphasized the development of biomarkers for early diagnosis, and discussed culturally specific interventions for dementia prevention and improving quality of life.
ALZHEIMERS & DEMENTIA
(2022)
Review
Biochemistry & Molecular Biology
Felix Javier Jimenez-Jimenez, Hortensia Alonso-Navarro, Elena Garcia-Martin, Jose A. G. Agundez
Summary: Coenzyme Q(10) has been studied for its potential therapeutic effects in Alzheimer's disease and other neurodegenerative diseases. While AD patients have similar levels of CoQ(10) in their blood compared to controls, experimental models suggest that CoQ(10) may have neuroprotective effects. Further research is needed to determine the therapeutic role of CoQ(10) in AD and cognitive decline.
Article
Biochemistry & Molecular Biology
Ying Xue, Xiangqun Xie
Summary: This study explores the potential impact of metformin on the development of severe dementia in individuals with AD and T2DM. The findings suggest that metformin usage is not significantly associated with a decreased risk of severe dementia, regardless of APOE epsilon 4 carrier status.
Review
Biochemistry & Molecular Biology
Maryam Faiyaz, Mohd Azhardin Ganayee, Salman Akhtar, Saravanan Krishnan, Bableen Flora, Deeksha Dogra, Niraj Kumar Jha, Dinesh Kumar Chellappan, Poonam Negi, Kamal Dua, Kavindra Kumar Kesari, Piyush Kumar Gupta
Summary: Alzheimer's disease is a progressive neurodegenerative disease that leads to dementia and impairment of cognitive functions. Nanomedicines developed due to the onset of nanotechnology offer a potential therapeutic strategy against AD by passing through the blood-brain barrier. Researchers are exploring new targets and therapeutics for Alzheimer's disease, as current medications are only symptomatic and lack an absolute cure.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2021)
Editorial Material
Neurosciences
Rose Bruffaerts, David Crosiers
Summary: This article introduces real-world multicentric data on the treatment of neuropsychiatric symptoms in patients with frontotemporal degeneration (FTD), highlighting the importance of knowledge sharing among clinicians. The authors also emphasize the need for improved collection of clinical data to provide more robust evidence for future therapies in FTD and other rare neurological diseases.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Neurosciences
Kasper Katisko, Johanna Kruger, Helmi Soppela, Paivi Hartikainen, Aivi Hartikainen, Annakaisa Haapasalo, Anne M. Remes, Eino Solje
Summary: Patients with frontotemporal dementia (FTD) often receive psychiatric misdiagnoses and are treated with off-label psychopharmacological medications prior to diagnosis. Female gender and behavioral variant of FTD phenotype alongside with depressive and psychotic symptoms are associated with the use of these medications.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
